Lords Mark Industries has unveiled an ambitious growth strategy, projecting a revenue surge to ₹2,638 crore by FY29. The roadmap emphasizes scaling its MedTech, dialysis, and renewable energy segments, alongside a proposed FPO in FY27 and a business demerger in FY28 to unlock shareholder value.
Lords Mark Industries Unveils Ambitious FY29 Growth Strategy
Revenue projected to hit ₹2,638 crore by FY29; EBITDA targets ₹398 crore by same period.
Reader Takeaway: Growth hinges on MedTech scaling and renewable contract execution; watch the FY27 capital raise plans closely.
What just happened
Lords Mark Industries released an investor presentation detailing a strategic shift toward becoming an integrated MedTech and sustainable infrastructure conglomerate. The company expects to achieve a revenue CAGR of approximately 25.2% from FY26 to FY29. Core segments driving this growth include In-Vitro Diagnostics (IVD), dialysis services via its Renalyx Health subsidiary, and renewable energy infrastructure.
Why this matters
The roadmap provides clear visibility into management's long-term value creation plan. Key events include a planned ₹500 crore capital raise in FY27 for manufacturing expansion and a proposed demerger of the MedTech business in FY28. These moves are intended to transition the company away from its traditional roots and toward higher-margin, specialized sectors.
Business and Operational Update
The MedTech division is gaining traction with over 200 IVD approvals and a recent $1 million order from the US market. In renewables, the company holds a ₹3,000+ crore pipeline, with ₹2,000 crore already secured from government agencies and PSUs like UPNEDA and EESL. The acquisition of an 85% stake in Renalyx Health Systems is positioned as a major growth engine starting in FY27.
Risks to watch
Management acknowledges risks regarding regulatory timelines for US FDA and CDSCO approvals. Furthermore, the company faces potential liquidity pressure from government payment cycles, though it intends to balance this by diversifying its client base toward private and export markets. Execution of capital expenditure and scaling in new manufacturing facilities remain primary operational risks.
What to track next
Investors should monitor the progression of the government-anchored order book and the formalization of the FY27 capital raise plans. The successful separation of the MedTech arm in FY28 will be the critical event for potential value unlocking.